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The oncogenic transcription factor c-Jun regulates
glutaminase expression and sensitizes cells to
glutaminase-targeted therapy
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Many transformed cells exhibit altered glucose metabolism and increased utilization of
glutamine for anabolic and bioenergetic processes. These metabolic adaptations, which
accompany tumorigenesis, are driven by oncogenic signals. Here we report that the
transcription factor c-Jun, product of the proto-oncogene JUN, is a key regulator of
mitochondrial glutaminase (GLS) levels. Activation of c-Jun downstream of oncogenic Rho
GTPase signalling leads to elevated GLS gene expression and glutaminase activity. In human
breast cancer cells, GLS protein levels and sensitivity to GLS inhibition correlate strongly with
c-Jun levels. We show that c-Jun directly binds to the GLS promoter region, and is sufﬁcient to
increase gene expression. Furthermore, ectopic overexpression of c-Jun renders breast cancer
cells dependent on GLS activity. These ﬁndings reveal a role for c-Jun as a driver of cancer cell
metabolic reprogramming, and suggest that cancers overexpressing JUN may be especially
sensitive to GLS-targeted therapies.
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T
he onset of proliferation imposes a range of biosynthetic
and bioenergetic demands on mammalian cells, which
are met by a fundamental reprogramming of cellular
metabolism1,2. The metabolic phenotype of proliferating cells,
including cancer cells, typically includes high rates of glucose
uptake and glycolysis coupled to lactate secretion (the Warburg
effect)3, elevated de novo nucleotide biosynthesis4, and a high ﬂux
of mitochondrial glutamine oxidation5–7. Increased nutrient
uptake and re-routing of metabolites into anabolic processes are
not passive adaptations to the proliferative state, but instead
are tightly regulated by the signal transduction pathways and
transcriptional networks that promote cell growth and cell cycle
progression. Thus, many of the oncogenic signals that lead to
cellular transformation directly impact cancer cell metabolism8.
Metabolic reprogramming supports the proliferative state
but can render cancer cells ‘addicted’ to certain nutrients, and
therefore provides opportunities for novel therapeutic interven-
tions9. Some cancer cells show an absolute requirement for an
exogenous supply of glutamine, the most abundant amino acid in
plasma. Glutamine has many metabolic fates inside the cell,
acting as a carbon and nitrogen source for biosynthetic reactions
and also contributing to redox homoeostasis5–7. However, it is the
role of glutamine as an anaplerotic substrate for the tricarboxylic
acid (TCA) cycle that underlies the ‘glutamine addiction’ of
many rapidly proliferating cells10,11. The sequential conversion of
glutamine to glutamate, and then to the TCA cycle intermediate
a-ketoglutarate (a-KG), provides a mechanism for replenishing
carbon that is lost from the cycle to anabolic pathways. The ﬁrst
reaction is catalysed by the mitochondrial enzyme glutaminase
(GLS), and the second reaction by glutamate dehydrogenase or by
one of several transaminase enzymes.
Two genes, GLS and GLS2, encode glutaminase enzymes in
mammals12. The GLS gene encodes two splice variants, referred
to as kidney-type glutaminase and glutaminase C (GAC),
while the GLS2 gene encodes two proteins through a surrogate
promoter mechanism, liver-type glutaminase and GAB12.
Whereas the GLS2 isozymes are downregulated in several
cancers13, the GLS isozymes, in particular the GAC splice
variant, are frequently upregulated in cancers of the breast14,
lung15, colon16, prostate17 and brain18. Recently, two classes of
small-molecule inhibitors of GLS have been identiﬁed, based on
the lead compounds bis-2-(5-phenylacetamido-1,2,4-thiadiazol-
2-yl)ethyl sulﬁde (BPTES) and 968 (refs 19,20). Inhibition of GLS
by these molecules, or siRNA-mediated knockdown of GLS,
severely impacts the proliferation and/or survival of several
cancer cell lines, but does not appear to have detrimental effects
on non-tumorigenic cells20,21. Thus, there is considerable interest
in targeting GLS as a therapeutic strategy against cancer, and the
BPTES derivative CB-839 is currently undergoing clinical trials21.
One regulator of GLS expression and glutamine catabolism is
the transcription factor c-Myc22,23. In P493 Burkitt’s lymphoma
and PC3 prostate cancer cell lines, c-Myc upregulates GLS
through an indirect mechanism involving transcriptional
repression of micro-RNAs miR-23a/b, which target the 30-UTR
of the GLS transcript and suppress its translation23. However, the
relationship between c-Myc and glutamine metabolism is
complex and tissue speciﬁc24, and tumour-speciﬁc alternative
polyadenylation of the GLS transcript can cause a switch of the
30-UTR, allowing it to escape c-Myc/miR-23-mediated
regulation25. An apparent uncoupling of c-Myc and GLS has
recently been described in human mammary epithelial cells as
well as in certain breast cancer cell lines26,27.
We previously reported that mitochondrial glutaminase
activity becomes elevated during Rho GTPase-mediated cellular
transformation20. Here we show that the oncogenic transcription
factor c-Jun is essential for this signalling outcome, and also acts
as a primary regulator of GLS expression in human breast cancer
cells. Moreover, we demonstrate that overexpression of the JUN
proto-oncogene is sufﬁcient to sensitize breast cancer cells to
glutaminase-targeted therapy.
Results
Rho GTPases can drive glutamine-dependent transformation.
We previously reported that oncogenic-Dbl, a guanine nucleotide
exchange factor and potent activator of Rho GTPases, signals
to upregulate mitochondrial GLS activity in NIH/3T3 cells20.
This is an essential event for maintaining Dbl-induced cellular
transformation. To explore further the signalling connections
that link Rho GTPases with GLS, we utilized an inducible,
tetracycline-off, system to control the expression of oncogenic-
Dbl in mouse embryonic ﬁbroblasts (MEFs). When doxycycline
(0.6 mgml 1) is present in the culture medium, HA-tagged
oncogenic-Dbl is undetectable by western blot analysis of whole-
cell lysates. Removal of doxycycline triggers a robust expression
of oncogenic-Dbl within 10 h that remains elevated through 72 h
(Fig. 1a). This is accompanied by a corresponding increase in GLS
protein levels, which peak 24–48 h following induction (Fig. 1a).
We isolated mitochondria from uninduced and induced MEFs
and assayed the preparations for glutaminase activity as described
previously28. This conﬁrmed that induction of oncogenic-Dbl
results in elevated glutaminase activity (Fig. 1b). We then tested
whether GLS was upregulated at the transcriptional level. Cells
that were either uninduced or induced (24 h) were analysed by
real-time PCR (RT–PCR), which revealed that induction of
oncogenic-Dbl expression leads to an B12-fold increase of the
GLS transcript (Fig. 1c).
Induction of oncogenic-Dbl caused MEFs to acquire transformed
characteristics, including greatly increased saturation density, and
the ability to proliferate in low serum (0.5% fetal bovine serum
(FBS)) medium and to undergo anchorage-independent growth.
Since these changes were accompanied by an increase in GLS levels,
we tested whether cellular transformation was dependent on an
exogenous supply of glutamine, and/or on GLS enzymatic activity.
After 8 days of culture in medium supplemented with 10%
FBS±4mM glutamine, saturation density was assessed by ﬁxing
and staining cells with crystal violet (Fig. 1d). Prior to ﬁxation, cells
were imaged at  100 magniﬁcation (Supplementary Fig. 1a). The
increased saturation density of cells expressing oncogenic-Dbl was
completely abolished in glutamine-free medium, but could be
partially rescued by supplementation with a cell-permeable analogue
of a-ketoglutarate (dimethyl-a-KG), a downstream metabolite of
the GLS reaction. We compared cell viability under high-glutamine
(4mM) and low-glutamine (0.2mM) conditions, and found that
uninduced cells remained fully viable following glutamine depletion,
whereas induced cells showed an B5-fold increase in cell death
(Fig. 1e). The proliferation rate of both uninduced and induced cells
decreased on glutamine deprivation, although the inhibition was
B2-fold greater in induced cells (Fig. 1f).
We then used BPTES19, a small-molecule inhibitor of GLS, to
test whether MEFs transformed by oncogenic-Dbl were
dependent on GLS activity. Saturation density of induced cells
was decreased by BPTES treatment in a dose-dependent manner,
and partially rescued by supplementation with dimethyl-a-KG
(Fig. 1g and Supplementary Fig. 1b). Cell proliferation assays
illustrated the remarkable difference in BPTES sensitivity between
uninduced and induced MEFs (Fig. 1h). Proliferation of induced
cells was potently inhibited by BPTES with an IC50 of 8 mM,
whereas uninduced cells were unaffected even by 20mM BPTES.
Oncogenic-Dbl-induced cells, but not uninduced cells, were
capable of anchorage-independent growth. This too was
completely blocked by BPTES treatment (Fig. 1i).
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Rho GTPases signal to c-Jun to upregulate GLS expression.
The results above show that oncogenic-Dbl signals to upregulate
GLS at the transcript and protein level, and that cellular
transformation driven by oncogenic-Dbl is dependent on GLS
activity and an exogenous supply of glutamine. We next wanted
to identify the signalling pathway downstream of the Rho
GTPases that was responsible for regulating GLS expression.
We ﬁrst used phospho-speciﬁc antibodies to assess the effects of
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Figure 1 | Glutamine-dependent transformation by oncogenic-Dbl. (a) Western blot analysis showing timecourse of oncogenic-Dbl expression in an
inducible MEF system, and downstream elevation of GLS levels. Cells were induced by plating in doxycycline-free growth medium, and samples were
collected at time-points up to 72 h. (b) Glutaminase activity assay using mitochondria isolated from MEFs in which oncogenic-Dbl expression was either
uninduced (þDox) or induced for 24 h (Dox). Activity is expressed per mg of total cellular protein, and data presented are the mean±s.d. of triplicate
assays. (c) RT–PCR analysis of uninduced and induced (24 h) MEFs, showing relative levels of the GLS transcript. The data presented are the RQ values,
with error bars marking RQ max and RQ min, from triplicate reactions. (d) Saturation density analysis showing the effect of glutamine withdrawal on
oncogenic-Dbl inducible MEFs. Dishes of uninduced (þDox) and induced (Dox) cells cultured in 4mM glutamine, or in glutamine-free medium±2mM
dimethyl a-ketoglutarate, were ﬁxed and then stained with crystal violet. (e) Cell death analysis for uninduced or induced cells after 6 days culture in 4.0 or
0.2mM glutamine. Data presented are the mean±s.d. of triplicate assays. (f) Cell proliferation assays showing the effect of glutamine depletion on
proliferation of uninduced and induced MEFs over 6 days. Data presented are the mean±s.d. of triplicate assays. (g) Saturation density analysis showing
the effect of the GLS inhibitor BPTES on oncogenic-Dbl induced MEFs. Induced (Dox) cells cultured in the absence or presence of BPTES (30 or
40mM)±2mM dimethyl a-ketoglutarate were ﬁxed and then stained with crystal violet. (h) BPTES dose curves showing the effect of different BPTES
concentrations on proliferation over 6 days of uninduced or induced MEFs. Fractional proliferation relative to untreated cells is shown. Assays were carried
out in 10% FBS medium, and data presented are the mean±s.d. of triplicate assays. (i) Anchorage-independent growth assay for uninduced (þDox) cells,
and for induced (Dox) cells cultured under increasing BPTES concentrations. Data presented are the mean±s.d. of triplicate assays. Differences were
analysed with Student’s t-test. *Po0.05, **Po0.01.
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oncogenic-Dbl induction on key cellular signalling proteins. Here,
and throughout the study, low-serum conditions (0.5% FBS) were
used for signalling experiments to minimize ‘background’ cellular
signalling activity. Western blot analysis of whole-cell lysates
revealed an extremely potent activation of the MKK4/c-Jun
N-terminal kinase (JNK) signalling axis on induction (24 h), and
downstream activating phosphorylation of the oncogenic tran-
scription factor c-Jun (Fig. 2a). c-Jun is known to autoregulate its
own gene expression in MEFs29,30 and, consistent with this, we
found that total c-Jun levels increased as well as phosphorylated
c-Jun levels (2-fold and 26-fold, respectively) (Fig. 2a and
Supplementary Fig. 2a). The JNK kinase MKK7 and the
Jun-family members JunB and JunD were expressed at low
levels, and phosphorylated forms could not be detected
(Supplementary Fig. 2b,c). Another target of MKK4, p38, was
phosphorylated downstream of oncogenic-Dbl, whereas the
activation status of ERK showed only a subtle change (Fig. 2b).
Rho-associated coiled-coil containing protein kinase (ROCK) was
likely activated, as indicated by increased phosphorylation of its
substrate myosin light chain 2 (MLC 2) (Fig. 2c). Consistent with
earlier reports that ROCK signals to inhibit Akt31, a modest
decrease in Akt phosphorylation at residue T308 occurred on
induction (Fig. 2d), and this could be rescued by inhibition of
ROCK (Supplementary Fig. 2d). The mTORC1-S6K signalling
axis showed little change on oncogenic-Dbl induction, and we
also detected no change in the phosphorylation level of AMPKa
(Fig. 2d).
Since ROCK, p38 and JNK signalling were all activated
downstream of oncogenic-Dbl, we tested whether selective
inhibition of these kinases (by the small-molecule inhibitors
Y-27632, SB203580 and SP600125, respectively) impacted the
ability of oncogenic-Dbl to upregulate GLS. Cells were induced
for 48 h, either in the absence or presence of 10mM of each
inhibitor, and whole-cell lysates were then analysed by western
blot. Treatment of induced cells with the ROCK inhibitor
Y-27632 or the p38 inhibitor SB203580 did not signiﬁcantly
impact GLS levels, whereas the JNK inhibitor SP600125 largely
blocked the upregulation of GLS (Fig. 3a). Although rapamycin-
sensitive mTORC1 can inﬂuence GLS levels by increasing MYC
translation32, we found that regulation of GLS downstream of the
Rho GTPases was independent of mTORC1 activity (Fig. 3b), and
changes in c-Myc (and phospho-c-Myc) levels did not fully
correspond to changes in GLS (Supplementary Fig. 2e).
Treatment of induced cells with the c-Myc inhibitor 10058-F4
severely impacted viability in low-serum (0.5% FBS) culture
medium (no viable cells remained after 24 h treatment with
10 mM 10058-F4), and it is possible that c-Myc contributes to the
regulation of GLS expression by Rho GTPases under these
conditions. In high-serum (10% FBS) medium, treatment with
10058-F4 at concentrations up to 60 mM had little impact on GLS
levels in induced cells (Supplementary Fig. 2f), whereas inhibition
of JNK by 10 mM SP600125 still suppressed GLS expression
(Supplementary Fig. 2e).
Consistent with the effects on GLS protein levels, treatment
with the JNK inhibitor SP600125 (10 mM) completely blocked
the increase in mitochondrial glutaminase activity that occurs
downstream of oncogenic-Dbl signalling (Fig. 3c). Because
JNK directly phosphorylates activator protein 1 (AP-1) family
transcription factors including the archetypal substrate c-Jun,
leading to increased transcriptional activity, we tested whether
blockade of JNK signalling affected GLS transcript levels.
The B12-fold increase in GLS mRNA that occurs following
oncogenic-Dbl induction was completely abolished by 10 mM
SP600125 (Fig. 3d). To test the hypothesis that the effects of JNK
inhibition were mediated by suppression of c-Jun transcriptional
activity, we treated induced cells with 10mM SR11302, a selective
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Figure 2 | Oncogenic-Dbl potently activates the MKK4-JNK-c-Jun signalling axis in MEFs. Western blot analysis of whole-cell lysates of MEFs in
which oncogenic-Dbl expression was either uninduced (þDox) or induced for 24 h (Dox) under low-serum (0.5% FBS) conditions. The extent of
activation of different signalling pathways was assessed using phospho-speciﬁc antibodies that recognize activated kinases or their downstream
phosphorylation targets (left panels). Any changes in total protein levels were also assessed (right panels). (a) The MAPK signalling axis involving
MKK4-JNK-c-Jun is potently activated downstream of oncogenic-Dbl. Total c-Jun levels are also elevated, consistent with previous reports showing
auto-regulation of JUN expression. (b) The MAPK p38 is moderately activated, whereas ERK is only slightly activated on oncogenic-Dbl induction.
(c) ROCK activity, as read-out by MLC 2 phosphorylation, is activated on induction. (d) Akt is slightly inhibited, and AMPK and mTORC1 activity (the latter
read-out by S6K phosphorylation) are largely unaffected by oncogenic-Dbl induction. Relative densitometry data are the mean±s.d. of triplicate blots.
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Figure 3 | Oncogenic-Dbl signals to c-Jun to upregulate GLS in MEFs. (a) Western blot analysis of whole-cell lysates of uninduced (þDox) or induced
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upregulation of GLS downstream of oncogenic-Dbl. (b) Western blot analysis showing that inhibition of mTORC1 by rapamycin has little effect on the
upregulation of GLS downstream of oncogenic-Dbl. (c) Glutaminase activity assay using mitochondria isolated from uninduced (þDox) MEFs and from
MEFs that had been induced for 24 h (Dox) in the absence or presence of 10mM SP600125 (JNK inhibitor). Activity is expressed per mg of total cellular
protein and data presented are the mean±s.d. of triplicate assays. (d) RT–PCR analysis of uninduced (þDox) and 24 h induced (Dox) MEFs±10mM
SP600125, showing relative levels of the GLS transcript. The data presented are the RQ values, with error bars marking RQ max and RQ min, from triplicate
reactions. (e) Western blot analysis showing that the AP-1 inhibitor SR11302 (10 mM) completely blocks GLS expression in oncogenic-Dbl-induced MEFs.
(f) RT–PCR analysis showing that transient transfection of uninduced (þDox) MEFs with constitutively activated JNK/MKK fusion constructs leads
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(g) Western blot analysis of the samples from the previous panel, showing that ectopic expression of constitutively activated JNK fusion constructs in
uninduced MEFs leads to increased phosphorylation of c-Jun and upregulated GLS protein levels. (h) RT–PCR analysis showing that transient transfection of
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inhibitor of the AP-1 family of transcription factors to which
c-Jun belongs33. This resulted in the complete loss of GLS to
undetectable levels (Fig. 3e).
The experiments above suggested that the signal to elevate GLS
expression downstream of oncogenic-Dbl is transmitted via JNK-
mediated phosphorylation of a Jun-family AP-1 transcription factor,
most likely c-Jun, since it is highly expressed in these cells (Fig. 2a),
in contrast to JunB and JunD (Supplementary Fig. 2c). To test
whether JNK and c-Jun can upregulate GLS expression, we
transiently transfected uninduced MEFs with constructs for
expressing constitutively activated MKK/JNK fusion proteins34 or
c-Jun. Uninduced cells were cultured for 48 h after transfection (in
10% FBS medium, as transfection reagents harmed viability of MEFs
in 0.5% FBS medium), and then analysed by RT–PCR and western
blot. Ectopic expression of JNK1, JNK2 or JNK3 fusion-constructs
all led to elevated GLS transcript levels relative to vector-control cells
(Fig. 3f). Western blot analyses of whole-cell lysates showed that
phospho-c-Jun and GLS were both elevated downstream of the JNK
constructs (Fig. 3g). Similarly, ectopic expression of the JUN gene
resulted in upregulated GLS transcript levels (Fig. 3h), and elevated
levels of both phospho-c-Jun and GLS (Fig. 3i).
Collectively, these results indicate that, downstream of
oncogenic Rho GTPase signalling, JNK transmits a signal to
increase transcription of the GLS gene by phosphorylating and
activating the oncogenic transcription factor c-Jun. This
prompted us to investigate the possible role of c-Jun in regulating
GLS expression in human cancer cells.
c-Jun and GLS correlate in human breast cancer cell lines.
Because the JUN proto-oncogene is overexpressed, and associated
with aggressive behaviour, in a subset of human breast
cancers35–37, we probed a panel of 12 breast cancer cell lines for
c-Jun and GLS. First, we obtained an estimate of the glutamine
dependence of each cell line by assaying proliferation over 6 days
in culture medium containing either 2.0 or 0.1mM glutamine
(Supplementary Fig. 3). We then collected cells at B60%
conﬂuency from complete RPMI medium (10% FBS, 2mM
glutamine) and probed whole-cell lysates by western blot, with
samples ordered by increasing glutamine dependence of the cell
line, left to right. This revealed a very strong correlation
(R¼ 0.85) between relative levels of c-Jun and GLS (Fig. 4a and
Supplementary Fig. 4a). In particular, cell lines with high
endogenous c-Jun levels (BT-549, Hs 578T, MDA-MB-231 and
TSE) all showed highly elevated GLS levels. The level of c-Jun also
correlated very strongly with the glutamine dependence of the
cell lines (R¼ 0.83; see Supplementary Fig. 4b) and moderately
strongly with their proliferation rates (R¼ 0.63; see
Supplementary Fig. 4c). The abundance of activated c-Jun, as
indicated by phosphorylation at residue S73 (a JNK target
residue), similarly correlated very strongly with GLS (Fig. 4a),
whereas the related Jun-family transcription factors, JunB and
JunD, showed less correlation (Fig. 4b). Relative levels of
glutamate dehydrogenase (GLUD1/2) showed little variation
among the cell lines (Supplementary Fig. 5).
The JNK1 and JNK2 proteins each exist as two splice
variants, p46 (predominantly JNK1) and p54 (predominantly
JNK2)30,38,39. Whereas p46 JNK1 is the primary kinase for
activating c-Jun, endogenous p54 JNK2 can negatively regulate
c-Jun stability30. We found that p46 JNK is expressed and
phosphorylated to a similar extent across the panel of breast
cancer cell lines (Fig. 4c). In contrast, although p54 JNK is
expressed in all cell lines, it only shows strong phosphorylation in
ZR-75-1 and CAMA-1 (Fig. 4c). Given that p46 JNK is activated
in all cell lines, and that phosphorylated c-Jun is proportional to
total c-Jun across the panel (Fig. 4a), we conclude that differences
in total c-Jun activity between the cell lines are due primarily to
variations in c-Jun protein levels, rather than to differences in
JNK activity.
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Figure 4 | c-Jun correlates strongly with GLS levels in human breast
cancer cell lines. Cells were collected at B60% conﬂuency from RPMI
growth medium supplemented with 10% FBS, and whole-cell lysates
prepared and analysed by western blot. Samples were ordered according
to glutamine dependence, increasing from left to right (Supplementary
Fig. 3). (a) Correlation between c-Jun/phospho-c-Jun and GLS levels.
Quantiﬁcation of GLS and c-Jun band intensities allowed a Pearson
correlation coefﬁcient of 0.85 to be determined (Supplementary Fig. 4a).
(b) Other Jun-family members do not correlate strongly with GLS levels.
(c) Under 10% FBS culture conditions, p46 JNK (lower band) is active in all
of the breast cancer cell lines. Neither JNK nor phospho-JNK correlate with
GLS levels. (d) Other reported regulators of GLS expression do not strongly
correlate with GLS levels.
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We also probed lysates for three previously reported regulators
of GLS, namely c-Myc and STAT1 that upregulate GLS22,23,40,
and the retinoblastoma protein (Rb), loss of which leads to
elevated GLS levels through an unknown mechanism41 (Fig. 4d).
None of these proteins correlated with GLS, although we note
that all three are subject to post-translational regulation.
The GLS promoter directly binds c-Jun at a consensus motif.
We next examined whether c-Jun binds directly to the GLS
promoter. The promoter region for the human GLS gene was
analysed to position  5,000 bp relative to the transcription start
site (TSS), and a number of putative c-Jun binding sites (o15%
dissimilarity to the consensus sequence) were identiﬁed using the
PROMO42 resource (Supplementary Fig. 6). An earlier genome-
wide survey of c-Jun binding sites found them to be located in
close proximity to the TSS, and mammalian transcription factor
binding sites in general are strongly enriched around  200 bp
from the TSS35,43. We found a close match to the consensus c-Jun
binding motif (TGA[G/C]TCA) at position  188 bp relative to
the TSS of human GLS (50-TGACTCC-30) (Supplementary Figs 6
and 7a). A close match to the c-Jun consensus motif is also
present at position  200 bp in the mouse GLS promoter
(50-TGACACA-30) (Supplementary Fig. 7b). Exact matches to
the c-Jun consensus motif (50-TGAGTCA-30) were also found at
position  2,211 bp for human GLS, and positions  2,469 and
 1,545 bp for mouse GLS.
We then carried out chromatin immunoprecipitations (ChIPs)
to test whether c-Jun binds directly to the GLS promoter. For
these experiments, we used MDA-MB-231 breast cancer cells,
which have high endogenous levels of both GLS and c-Jun
(Fig. 4a). Brieﬂy, cross-linked chromatin was digested to a length
ofB150–900 bp, and an antibody against endogenous c-Jun was
used to immunoprecipitate c-Jun/DNA complexes. A parallel
immunoprecipitation was carried out using IgG, as a negative
control. Protein-DNA cross-links were then reversed, and
RT–PCR was performed using primers designed to amplify a
196-bp fragment centred on the putative c-Jun binding site at
position  188 bp relative to the TSS (Supplementary Fig. 7a).
This yielded a strong signal from the c-Jun ChIP relative to the
IgG ChIP, indicating that c-Jun binds to this region of the GLS
promoter (Fig. 5a). Similar results were obtained using two
additional sets of primers to amplify slightly shorter fragments
also centred on the predicted c-Jun binding site (Supplementary
Fig. 8).
c-Jun regulates GLS expression and BPTES sensitivity. Since
c-Jun directly binds the promoter of the GLS gene, and endo-
genous levels of c-Jun and GLS correlate strongly in human breast
cancer cell lines, we determined whether inhibition of JNK,
inhibition of AP-1 family transcription factors, or knockdowns of
c-Jun, affected GLS levels in these cells. We ﬁrst inhibited JNK
using 15mM SP600125 in the high-GLS cell lines MDA-MB-231
and TSE. This led to a sharp decrease in phospho-c-Jun levels,
and GLS expression was strongly suppressed within 24 h and
remained so through 72 h (Fig. 5b). We also directly inhibited
AP-1 transcriptional activity in MDA-MB-231 cells using
SR11302 (48 h), and observed a dose-dependent suppression of
GLS expression (Fig. 5c). Reciprocally, ectopic expression of a
constitutively activated JNK1 fusion protein in MDA-MB-231
cells, under low serum (0.5% FBS) conditions, resulted in elevated
c-Jun phosphorylation and elevated GLS levels (Fig. 5d).
In BT-549 cells, which are reported to be relatively drug-
resistant44, treatment with 15 mM SP600125 caused only a very
modest inhibition of c-Jun phosphorylation (Fig. 5e, left panel).
Consistent with this, SP600125 treatment did not lead to
decreased GLS levels in this cell line, and we therefore used
siRNAs to knockdown JUN expression. Prolonged depletion of
c-Jun in BT-549 cells (and in other cell lines with high
endogenous c-Jun levels) could not be tolerated and resulted in
cell death. Nevertheless, whole-cell lysates from BT-549 cells
treated with JUN-targeted siRNAs and collected after 48 h
repeatedly showed that GLS levels were lower in c-Jun-depleted
cells (Fig. 5e, right panel). Quantiﬁcation of band intensities
conﬁrmed that the degree of c-Jun depletion correlated with the
degree of GLS depletion.
The results above indicate that the relationship between c-Jun
and GLS levels in breast cancer cells is not only correlative but is
also causative. We therefore examined whether cell lines with
high c-Jun levels are more sensitive to the GLS inhibitor BPTES.
Proliferation assays were carried out for all 12 breast cancer cell
lines under a range of BPTES concentrations. Deﬁning highly
sensitive cell lines as those with an IC50o10mM BPTES, none of
the eight cell lines with low c-Jun levels were highly sensitive to
BPTES, whereas three of the four cell lines with high c-Jun levels
were highly sensitive (Supplementary Table 1). The one exception
was the drug-resistant cell line BT-549. Representative dose
curves for a highly sensitive cell line (MDA-MB-231, IC50¼ 1.8
mM), a moderately resistant cell line (T-47D, IC50¼ 20mM), and
a highly resistant cell line (CAMA-1, IC50¼ n/a) are shown
(Fig. 5f). The much greater BPTES sensitivity of the high c-Jun
cell lines, Hs 578T, MDA-MB-231 and TSE, relative to the low
c-Jun lines, is illustrated by the response to 2 mM BPTES (Fig. 5g
and Supplementary Fig. 9).
Inhibition of JNK by SP600125 led to a sharp decrease in GLS
levels in MDA-MB-231 (and other) breast cancer cells (see
above). We therefore carried out proliferation assays to compare
BPTES sensitivity of MDA-MB-231 cells cultured in the absence
or presence of 15mM SP600125. Treatment with the JNK
inhibitor sharply decreases the proliferation rate relative to
untreated cells. However, the slow proliferation that still occurs in
the presence of SP600125 is markedly desensitized to BPTES,
with the IC50 for BPTES shifting B7-fold from 1.8 to 12 mM
(Fig. 5h).
c-Jun is sufﬁcient to elevate GLS in breast cancer cells. Using
the MDA-MB-468 breast cancer cell line, which exhibits relatively
low endogenous levels of c-Jun and moderate levels of GLS
(Fig. 4a), we generated derivative cell lines that stably overexpress
JUN-V5 or carry the empty plasmid vector. We then collected
vector-control cells and JUN-overexpressing cells at B60% con-
ﬂuency from RPMI medium (10% FBS, 2mM glutamine), and
probed whole-cell lysates for GLS, c-Jun and V5-tag by western
blot (Fig. 6a). This showed that GLS levels are elevated in the
JUN-overexpressing cells relative to the vector-control cells.
Mitochondria isolated from the two cell lines were assayed
for glutaminase activity, which was markedly higher in the
JUN-overexpressing cells (Fig. 6b). Moreover, RT–PCR analysis
conﬁrmed that GLS transcript levels were upregulated in
JUN-overexpressing cells relative to vector-control cells (Fig. 6c).
We made equivalent derivative cell lines of the MCF7 parental
cell line, which has very low endogenous levels of both c-Jun
and GLS (Fig. 4a), and similarly found that GLS expression
was upregulated in JUN-overexpressing cells (Supplementary
Fig. 10a).
The level of c-Myc did not vary between the vector-control and
JUN-overexpressing cells (Fig. 6d), and treatment with the c-Myc
inhibitor 10058-F4 at concentrations up to 60 mM (48 h) had little
effect on GLS levels in the derivative cell lines (Fig. 6e and
Supplementary Fig. 10b). In contrast, treatment with the
AP-1 inhibitor SR11302 (1–10 mM) caused a dose-dependent
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Figure 5 | Inhibition of c-Jun suppresses GLS expression and BPTES sensitivity in human breast cancer cell lines. (a) ChIP analysis showing that c-Jun
binds to the GLS promoter. Complexes containing c-Jun were immunoprecipitated from cross-linked, digested, chromatin isolated from MDA-MB-231 cells.
A parallel immunoprecipitation using rabbit IgG was carried out as a negative control. Following reversal of cross-links and puriﬁcation of DNA, RT–PCR was
run using primers designed to amplify a 196-bp fragment centred on the putative c-Jun binding site at position  188 bp relative to the TSS. The data
presented are the RQ values, with error bars marking RQ max and RQ min, from triplicate reactions. (b) Western blot analysis showing that treatment of
MDA-MB-231 or TSE cells with the JNK inhibitor SP600125 (15mM) leads to decreased phosphorylation of c-Jun, and decreased GLS levels. (c) Treatment
of MDA-MB-231 cells with the AP-1 inhibitor SR11302 (1–10mM) for 48 h results in a dose-dependent decrease in GLS. (d) Western blot analysis showing
that transient transfection of MDA-MB-231 cells with a constitutively activated JNK fusion construct results in increased c-Jun phosphorylation and
upregulated GLS levels. Cells were collected 48 h after transfection. (e) Western blot analysis showing that in the drug-resistant breast cancer cell line
BT-549, treatment with 15mM SP600125 has little effect on c-Jun phosphorylation and does not lead to decreased GLS levels (left panels). However,
knockdown of JUN expression using siRNAs leads to decreased GLS levels. Relative band intensities are indicated. (f) Representative BPTES dose curves
showing the effect of BPTES on the proliferation of breast cancer cell lines over 6 days. Curves were ﬁtted using SigmaPlot, with data from triplicate assays.
(g) Sensitivity of breast cancer cell lines to GLS inhibition, as indicated by inhibition of proliferation over 6 days by 2 mM BPTES. Of the high-c-Jun lines, only
the drug-resistant BT-549 cells were not highly sensitive to BPTES. None of the low-c-Jun lines were highly sensitive. Data presented are the mean±s.d.
of triplicate assays. (h) BPTES dose curves for MDA-MB-231 cells±15mM SP600125, showing that inhibition of JNK desensitizes cells to GLS inhibition
(the IC50 for BPTES shifts from 1.8 to 12 mM). Curves were ﬁtted using SigmaPlot, with data from triplicate assays. Relative densitometry data are the
mean±s.d. of triplicate blots.
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suppression of GLS in both cell lines, an effect that was especially
pronounced in the JUN-overexpressing cells (Fig. 6f).
Overexpression of JUN sensitizes cancer cells to BPTES.
As described above, MDA-MB-231 cells treated with the JNK
inhibitor SP600125 become desensitized to the GLS inhibitor
BPTES (Fig. 5h). To complement this result, we carried out
proliferation assays to determine whether overexpression of
the JUN proto-oncogene is sufﬁcient to increase the BPTES
sensitivity of MDA-MB-468 cells. Although vector-control cells
showed some response to BPTES treatment, overexpression of
JUN greatly sensitized cells to BPTES treatment (Fig. 6g).
Supplementation of the medium with 1mM dimethyl a-KG
completely rescued cells from r12 mM BPTES, and partially
rescued cells from higher BPTES concentrations (Fig. 6g).
Although the parental and vector-control MDA-MB-468 cell lines
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Figure 6 | c-Jun increases GLS expression and BPTES sensitivity in breast cancer cells. (a) Western blot analysis of GLS and c-Jun levels in whole-cell
lysates of MDA-MB-468 cells, stably carrying either pCDNA3.1 or the JUN-V5 expression vector pCDNA3.1-JUN. Relative band intensities are indicated for
GLS. (b) Glutaminase activity assay using mitochondria isolated from the derivative MDA-MB-468 cell lines. Activity is expressed per mg of total cellular
protein, and data presented are the mean±s.d. of triplicate assays. (c) RT–PCR analysis of the derivative MDA-MB-468 cell lines, showing relative
abundance of the GLS transcript. The data presented are the RQ values, with error bars marking RQ max and RQ min, from triplicate reactions. (d) Western
blot analysis showing c-Myc levels in the derivative cell lines. (e) Western blot analysis showing that treatment of vector-control, or JUN-overexpressing,
MDA-MB-468 cells with the c-Myc inhibitor 10058-F4 at concentrations up to 60mM for 48 h has little effect on GLS levels. Relative band intensities are
indicated for GLS. (f) Western blot analysis showing that treatment with the AP-1 inhibitor SR11302 (1–10mM) for 48 h leads to a dose-dependent decrease
in GLS levels. The effect is especially pronounced in JUN-overexpressing cells. (g) Cell proliferation assays for MDA-MB-468 cells stably carrying
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plotted as a percentage. The data presented are the mean±s.d. of triplicate assays. Relative densitometry data are the mean±s.d. of triplicate blots.
Differences were analysed with Student’s t-test. *Po0.05, **Po0.01.
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showed little dependence on the GLS reaction, both are
moderately glutamine-dependent (Supplementary Figs 3 and 11).
This reﬂects the importance of an exogenous glutamine supply
for other metabolic processes that do not involve the GLS
reaction, such as nucleotide biosynthesis and protein synthesis.
Glutamine dependence of the JUN-overexpressing derivative
cell line was unchanged from that of the parental cells
(Supplementary Fig. 11).
c-Jun regulated transcript levels in invasive breast cancer.
To establish further the relationship between c-Jun activity and
GLS expression in breast cancer, we used the cBioportal45,46
suite of tools (www.cbioportal.org) to analyse data from The
Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma
(TCGA, provisional) data set (959 samples). In many cancers,
upregulation of c-Jun occurs at the post-transcriptional and
post-translational levels, but not at the transcriptional level
(see Discussion). Consequently, JUN mRNA levels are rarely
upregulated, even though c-Jun protein levels can be highly
elevated. Consistent with these ﬁndings, TCGA data showed that
JUN mRNA was elevated (z score 42.0) in only 3% of invasive
breast carcinoma samples. We therefore determined whether the
expression levels of some validated c-Jun transcriptional targets
correlate with those of GLS. We selected only conﬁrmed direct
targets of c-Jun (and not v-Jun) that contain a c-Jun binding site
within the promoter region35,47–49, and we eliminated from the
list those c-Jun target genes that are frequently altered at the
genomic level within the data set (for example, CCND1, ampliﬁed
in 16% of samples, and TP53, mutated in 31% of samples). Using
the resulting list of c-Jun targets (Supplementary Table 2), we
found that transcripts that are upregulated by c-Jun almost
invariably correlate positively with GLS mRNA levels, whereas
those targets that are transcriptionally repressed by c-Jun exhibit
a negative correlation with the GLS transcript (Fig. 7; see also
Supplementary Figs 12 and 13).
Discussion
In proliferating cells, the TCA cycle serves as a major source of
biosynthetic precursors. Metabolic intermediates that are lost to
anabolic pathways must be rapidly replenished, and the most
abundant carbon sources for these anaplerotic reactions are
glucose and glutamine. Indeed, anaplerosis is a key function
underlying the upregulated consumption of these nutrients by
cancer cells10,11,50. An important route for the delivery of
glutamine-derived carbon into the TCA cycle begins with the
hydrolysis of glutamine to glutamate, a reaction catalysed by
glutaminase. The TCA cycle intermediate a-ketoglutarate
can then be generated through the action of glutamate
dehydrogenase, or through transaminase activities.
In this study, we used an inducible MEF system for hyper-
activating Rho GTPase signalling, which we previously linked to
increased mitochondrial GLS activity in NIH-3T3 cells20, and also
to upregulated glutamine-mediated anaplerosis for oxidative TCA
cycle ﬂux in MEFs51. Ectopic expression of oncogenic-Dbl in
NIH-3T3 cells leads to elevated levels of the GLS transcript
(Supplementary Fig. 14a), but the lower background level of GLS
in MEFs relative to NIH-3T3 cells (Supplementary Fig. 14b)
allows for a much clearer read-out, by RT–PCR and especially by
western blot, of changes in GLS expression. By selectively
inhibiting signalling pathways activated downstream of the Rho
GTPases in the inducible system, we have now discovered that the
c-Jun N-terminal kinase (JNK) and the oncogenic transcription
factor c-Jun are critical for upregulating GLS at the transcript and
protein levels. We also found that in human breast cancer cell
lines, c-Jun levels correlate strongly with GLS levels and with
sensitivity to the GLS inhibitor BPTES. Moreover, we determined
that c-Jun directly binds the promoter of the GLS gene and
increases its expression. Importantly, this not only leads to
elevated mitochondrial glutaminase activity, but also causes
cancer cells to become more dependent on glutamine-mediated
anaplerosis.
The c-Jun transcription factor is the cellular homologue of
v-Jun, the transforming oncoprotein of avian sarcoma virus 17
(refs 52,53). A key role for c-Jun in both healthy and neoplastic
tissue is to drive cell cycle progression, and ﬁbroblasts derived
from JUN-null mouse embryos exhibit a severe defect in
proliferation54. The c-Jun protein is phosphorylated at the
M/G1 transition55, and loss of c-Jun or expression of mutants
defective for JNK-catalysed phosphorylation leads to a G2/M cell
cycle block56. One transcriptional target of c-Jun is the CCND1
gene, which encodes the G1 to S phase regulator cyclin D1
(ref. 57). c-Jun also binds to a variant AP-1 site in the TP53 gene
promoter, leading to suppression of p53 and of the p53-regulated
cyclin-dependent kinase inhibitor p21 (ref. 54). The net effect is
that c-Jun increases the activity of G1 cyclin-dependent kinase
complexes.
When taken together, these ﬁndings provide a biological
rationale for the positive regulation of GLS by c-Jun that
we describe. In order for sustained proliferation to occur,
signalling to the cell cycle machinery must be coordinated with
reprogramming of cellular metabolism to support biomass
accumulation. By simultaneously driving cell cycle progression
and upregulating GLS expression, c-Jun promotes cell
proliferation and also activates TCA cycle anaplerosis to replenish
metabolites that have been directed to biosynthetic pathways
(Fig. 8). Notably, two other reported regulators of GLS expression
are involved in cell cycle control. The Rb protein prevents G1 to
S phase progression58, and loss of this tumour suppressor leads
to upregulation of GLS41. Similarly, the oncogenic transcription
factor c-Myc promotes G1 to S phase transition, and is a positive
regulator of GLS expression22,23.
Mirroring the ability of v-Jun to cause avian sarcoma, the JUN
gene is highly ampliﬁed and overexpressed in aggressive human
sarcomas59, and in an analysis of copy number alterations across
3,131 diverse cancer samples, JUN was found to be signiﬁcantly
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Figure 7 | The GLS transcript correlates with established c-Jun target
transcripts in invasive breast cancer. Bar chart showing the Spearman
correlation coefﬁcients between mRNA levels of GLS and of established
c-Jun transcriptional targets. Transcripts that are upregulated by c-Jun are
shown in black, and almost exclusively correlate positively with GLS.
Transcripts that are repressed by c-Jun are shown in white, and all correlate
negatively with GLS. Correlation plots were prepared and correlation
coefﬁcients determined using the cBioportal suite of tools and data from
The Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma (TCGA,
provisional) data set.
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ampliﬁed across the entire data set60. In many cancers, protein
levels of c-Jun are highly upregulated even in the absence of JUN
ampliﬁcations or elevated transcription of the JUN gene. This can
be due to both translational activation and increased protein
stability. For example, c-Jun is highly elevated in melanoma cells
as a result of increased translation following loss of mi-R125b,
which binds to the coding region of the JUN transcript and
suppresses translation in normal melanocytes61. In breast cancer
cells, c-Jun is also upregulated at the protein level but not
at the transcriptional level37. One mechanism for this involves
downregulation of the tumour suppressor COP1 E3 ubiquitin
ligase, which targets c-Jun for degradation37. Indeed, among the
cell lines used in the present study, BT-549, Hs 578T and MDA-
MB-231 are reported to have low COP1 levels, whereas MCF7
and T47D have elevated COP1 (ref. 37).
For transcriptional activity, c-Jun and related transcription
factors must form a dimeric complex, which is known as AP-1
and consists of Jun–Jun or Jun–Fos dimers. Jun-family members
(c-Jun, JunB and JunD) can dimerize with themselves or with Fos
proteins, whereas Fos-family members (c-Fos, Fra-1, Fra-2 and
FosB) must heterodimerize with a Jun protein57. This raises
some questions concerning the ﬁne-tuning of GLS regulation.
Of the AP-1 transcription factors, c-Jun is the most potent
transcriptional activator. However, Jun-Fos heterodimers are
more stable and efﬁcient at driving transcriptional activation than
Jun–Jun dimers57. Importantly, the promoter speciﬁcity of dimers
containing c-Jun differs according to the dimerization partner,
and the relative abundances of potential partners vary between
cell types62,63. Consequently, the Jun- and Fos-family members
that are expressed within a given cell likely inﬂuence the
regulation of GLS expression by c-Jun, and it is possible that
JunB or JunD might substitute for c-Jun in some contexts.
High levels of c-Jun are associated with aggressive, invasive and
metastatic behaviour in breast cancer. Ectopic overexpression of
JUN in the MCF7 cell line leads to increased invasion and
tumorigenicity, whereas a dominant-negative variant of c-Jun
causes cell cycle arrest64,65. Several studies have found that c-Jun
is speciﬁcally elevated in triple-negative breast cancer (TNBC)
cells35,37,66 and MYC expression is also reported to be
upregulated in TNBC67. This could explain why TNBC cell
lines have higher GLS levels and greater sensitivity to the GLS
inhibitor CB-839 (a BPTES derivative) than receptor-positive
breast cancer cells21.
In conclusion, we have identiﬁed a JNK/c-Jun-dependent
signalling pathway that is responsible for upregulating GLS levels
during cellular transformation. Moreover, we show that the c-Jun
transcription factor is an important regulator of GLS expression
in breast cancer, and can drive cellular dependence on the
glutaminase reaction, thus conferring sensitivity to the GLS
inhibitor BPTES. Our ﬁndings link a key player in cell cycle
progression with a metabolic pathway that supports cell
proliferation, and illustrate that re-programming of cellular
metabolism is intricately connected with oncogenic transforma-
tion. Furthermore, our work reveals a novel function for the c-Jun
oncoprotein in cancer, and suggests why certain types of cancer
such as triple-negative breast cancer might be more susceptible to
glutaminase-targeted therapy.
Methods
Isogenic inducible MEF system for oncogenic-Dbl expression. The inducible
MEF line used in this study was generated as described previously51. Brieﬂy, the
gene encoding oncogenic-Dbl was sub-cloned into vector pTRE-HA (Clontech).
Parental MEFs containing the transcriptional transactivator tTA (Clontech) were
then co-transfected with the resulting pTRE-HA-onco-Dbl vector along with
vector pMET-puro, in a 20:1 ratio. Following puromycin selection (B3 weeks),
colonies were screened for inducible expression of oncogenic-Dbl. Cells were
maintained at 37 C, 5% CO2 atmosphere, in DMEM medium containing 4mM
glutamine (Gibco) and supplemented with 10% (v/v) tetracycline-free FBS (Gibco)
and 0.6 mgml 1 doxycycline. Expression of oncogenic-Dbl was induced by
re-plating cells in doxycycline-free medium (10% FBS). Residual doxycycline was
removed by replacing the medium (with the appropriate concentration of FBS,
and small-molecule inhibitor where relevant) after 5 h. Uninduced control samples
were treated in the same way: re-plating followed by media change at 5 h, but with
0.6 mgml 1 doxycycline present at all times. For glutamine-withdrawal
experiments, glutamine-free DMEM medium (Gibco) was supplemented with
dialysed FBS (Gibco). Growth medium containing other concentrations of
glutamine was prepared by mixing appropriate volumes of DMEM (4mM
glutamine) and glutamine-free DMEM.
Breast cancer cell culture and media. Breast cancer cell lines ZR-75-1,
BT-474, CAMA-1, SK-BR-3, T-47D, MCF7, MDA-MB-468, BT-549, Hs 578T,
MDA-MB-453 and MDA-MB-231 were obtained from the American Type Cell
Culture Collection (ATCC). The TSE breast cancer cell line was kindly supplied by
Dr Steven Abcouwer (University of Michigan). All breast cancer cell lines were
maintained at 37 C, 5% CO2 atmosphere, in RPMI 1640 medium containing
2mM glutamine (Gibco) and supplemented with 10% FBS (Gibco). For
glutamine-withdrawal experiments, glutamine-free RPMI 1640 medium (Gibco)
supplemented with 10% dialysed FBS (Gibco) was used. Cell lines were periodically
tested for Mycoplasma contamination.
DNA constructs. DNA primers were synthesized by Integrated DNA
Technologies. Plasmid pCDNA3.1/V5-His TOPO was purchased from Life
Technologies. The JUN gene was PCR ampliﬁed from plasmid pMIEG3-c-Jun,
which was a gift from Alexander Dent (Addgene plasmid # 40348)68, using primers
JUN_AMP_F (50-TTATGGATCCATGACTGCAAAGATGGAAACGACC-30) and
JUN_AMP_R (50-TTATGATATCAAATGTTTGCAACTGCTGCGTTAGC-30),
which added a BamH1 site and EcoRV site, respectively. The PCR product was
puriﬁed (QIAquick PCR puriﬁcation kit, QIAGEN), digested with BamH1 and
EcoRV (New England Biolabs), re-puriﬁed and ligated (T4 DNA ligase, New
England Biolabs) into pre-digested and puriﬁed pCDNA3.1/V5-His TOPO to yield
an expression vector for JUN-V5, pCDNA3.1-JUN. The construct was veriﬁed by
sequencing. The plasmids pCDNA3 Flag MKK7B2Jnk1a1 (Addgene plasmid #
19726)34, pCDNA3 Flag MKK7B2Jnk2a2 (Addgene plasmid # 19727)34 and
pCDNA3 Flag MKK7B2Jnk3a2 (Addgene plasmid # 19729)34 were all gifts
from Roger Davis.
Rho
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Figure 8 | c-Jun coordinates cell cycle progression with metabolic
reprogramming. Diagram summarizes the coordinated regulation of cell
proliferation by c-Jun. Transcriptional activity of c-Jun can be enhanced by
activating phosphorylations downstream of mitogenic signalling pathways,
including those mediated by the Rho family of GTPases. c-Jun can also
be upregulated by ampliﬁcation or increased expression of the JUN
proto-oncogene. A key role for c-Jun is to drive cell cycle progression, which
is achieved through transcriptional repression of cell cycle inhibitors and
transcriptional activation of cell cycle progression machinery. In this study,
we report that c-Jun also controls metabolic reprogramming to support
proliferation, by upregulating GLS expression and thereby stimulating
delivery of glutamine-derived carbon into the TCA cycle.
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Antibodies and reagents. Antibodies recognizing the following proteins were
purchased from Cell Signaling Technology: HA-tag (cat. no. 3724) used at 1:5,000,
a/b-tubulin (cat. no. 2148) used at 1:5,000, phospho-SEK1/MKK4 (S257) (cat. no.
4514) used at 1:2,000, phospho-MKK7 (S271/T275) (cat. no. 4171) used at 1:2,000,
phospho-JNK (T183/Y185) (cat. no. 4668) used at 1:2,000, phospho-c-Jun (S73)
(cat. no. 3270) used at 1:2,000, c-Jun (cat. no. 9165) used at 1:2,000, JunB (cat. no.
3753) used at 1:2,000, JunD (cat. no. 5000) used at 1:2,000, phospho-p38 MAPK
(T180/Y182) (cat. no. 4511) used at 1:2,000, p38 MAPK (cat. no. 8690) used at
1:2,000, phospho-ERK1/2 (T202/Y204) (cat. no. 4370) used at 1:2,000, ERK1/2 (cat.
no. 9102) used at 1:2,000, phospho-myosin light chain 2 (S19) (cat. no. 3675) used
at 1:1,000, myosin light chain 2 (cat. no. 3672) used at 1:1,000, phospho-AMPKa
(T172) (cat. no. 4188) used at 1:2,000, AMPKa (cat. no. 2603) used at 1:2,000,
phospho-Akt (T308) (cat. no. 9275) used at 1:2,000, Akt (cat. no. 9272) used at
1:2,000, phospho-p70 S6 kinase (T389) (cat. no. 9205) used at 1:2,000, p70 S6
kinase (cat. no. 9202) used at 1:2,000, STAT1 (cat. no. 9172) used at 1:2,000,
Rb (cat. no. 9309) used at 1:2,000, Glut1 (cat. no. 12939) used at 1:4,000, and c-Myc
(cat. no. 5605) used at 1:2,000. The antibody recognizing GLS was purchased
from Abgent (cat. no. AP8809b) and used at 1:8,000. Clariﬁcation of the bands
recognized by this antibody is shown in Supplementary Fig. 15. Antibodies
recognizing MKK4 (MEK4) (cat. no. ab33912), MKK7 (MEK7) (cat. no. ab52618)
and phospho-c-Myc (T58þ S62) (cat. no. ab10568), all used at 1:4,000, were
purchased from Abcam. Antibodies recognizing JNK (cat. no. sc-571) and
GLUD1/2 (cat. no. sc-160383), both used at 1:2,000, were purchased from Santa
Cruz Biotechnology. The antibody recognizing V5-tag was purchased from Life
Technologies (cat. no. R960) and used at 1:5,000. Secondary antibodies used,
as appropriate, were Cell Signaling Technology anti-rabbit IgG, HRP-linked
(cat. no. 7074) or anti-mouse IgG, HRP-linked (cat. no. 7076), or Santa Cruz
Biotechnology donkey anti-goat IgG-HRP (cat. no. sc-2020). BPTES was
synthesized and kindly provided by Dr Scott Ulrich, Ithaca College. ROCK
inhibitor Y-27632 (10mM solution in DMSO), the JNK inhibitor SP600125
(50mM solution in DMSO) and G418 were purchased from Calbiochem. All
other reagents were purchased from Sigma-Aldrich unless otherwise stated.
Western blot analysis. Whole-cell lysates were prepared in lysis buffer (50mM
HEPES pH 8.0, 150mM NaCl, 1mM Na3VO4, 25mM NaF, 1% (v/v) Triton X-100,
1mM MgCl2, 50mM b-glycerophosphate, 30mgml 1 leupeptin, 5 mgml 1
aprotinin) and insoluble debris was pelleted by centrifugation and removed.
Protein concentration was determined by Bradford assay (Bio-Rad), and lysate
proteins denatured by boiling for 5min in reducing SDS-sample buffer. Lysate
proteins (20mg total protein/lane) were then resolved on Novex 4–20% Tris-glycine
mini or midi protein gels (Life Technologies), and transferred to polyvinylidene
diﬂuoride membranes (PerkinElmer). Membranes were blocked in 7% bovine
serum albumin in tris-buffered saline and tween 20 (TBST) for 1 h at room tem-
perature, and probed overnight at 4 C in primary antibody solution (manufacturer
recommended concentration) in TBST. They were then washed in TBST, and
incubated in TBST solution containing 25% (v/v) non-fat dry milk powder and
appropriate secondary antibody at the manufacturer’s recommended concentration
for 1 h. Finally, the membranes were washed in TBST, and bands imaged using
Western Lightning Plus-ECL (PerkinElmer) and HyBlot ES autoradiography ﬁlm
(Denville Scientiﬁc Inc.).
MEF saturation density analysis. DMEM medium supplemented with 10%
FBS±0.6 mgml 1 doxycycline was added to 60mm dishes (3ml per dish), and
dishes were then seeded with 1 105 MEFs per dish. Following cell attachment
(5 h), growth medium was replaced with fresh medium containing appropriate
supplements. Growth medium was subsequently replaced at 48 h intervals. At day
8, growth medium was removed and 1.5ml 3.7% formaldehyde solution in H2O
was added for 30min. The formaldehyde solution was removed, and 1.5ml crystal
violet solution was added for 20min at room temperature. This was then removed,
and dishes washed four times with 3ml H2O and allowed to dry before imaging.
MEF anchorage-independent growth assay. Uninduced or oncogenic-Dbl-
induced MEFs were seeded at a density of 8,000 cells per ml in medium containing
0.3% (w/v) agarose, onto underlays of medium containing 0.6% agarose, in six-well
plates. Both layers of medium were supplemented with appropriate concentrations
of doxycycline (uninduced cells) and BPTES. Cultures were fed every 3 days, and
the total number of colonies was counted after 15 days.
Cell proliferation assays. Culture medium supplemented with glutamine or with
inhibitors at the described concentrations was added to 12-well plates (1ml per
well), and wells were seeded with cells at day 0 as follows (numbers optimized
to avoid over-conﬂuence during the assay). TSE cells: 5 103 cells per well.
MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-549: 1 104 cells per well. Hs
578T, MCF7, T-47D, CAMA-1, SK-BR-3, BT-474: 1.5 104 cells per well. ZR-75-1:
2 104 cells per well. Following cell attachment, growth medium was replaced at
12 h and subsequently every 48 h. At day 6, cells were trypsinized, suspended in an
appropriate volume of medium, and a hemacytometer was used to determine the
total number of cells per well. All cell proliferation assays were carried out in
triplicate, and the mean and s.d. calculated.
Mitochondrial isolation. Mitochondria were isolated using the Qproteome
mitochondria isolation kit (QIAGEN), following the manufacturer’s instructions.
For MEFs grown in low-serum media, 3 15 cm dishes of cells at B70%
conﬂuency were collected, and for MDA-MB-468 cells, 2 15 cm dishes of cells
at B70% conﬂuency were collected. The total protein of the starting material
(collected cells) and of the isolated mitochondria suspension was measured by
Bradford assay (Bio-Rad). This allowed glutaminase activity to be determined
per unit of total cellular protein (see below).
Mitochondrial glutaminase activity assay. A two-step protocol was used to assay
glutaminase activity, as previously described28. In the ﬁrst reaction, glutaminase
catalyses the hydrolysis of glutamine to glutamate, and in the second reaction
glutamate dehydrogenase catalyses the oxidative deamination of glutamate to form
a-ketoglutarate and NADH, which can be measured through its absorbance at
340 nm. Brieﬂy, mitochondria (10mg total protein) were added to 105 ml of reaction
mix 1 (20mM glutamine, 0.2mM EDTA, 50mM Tris-acetate, pH 8.6). Samples
were rotated at 37 C for 45min. The reaction was then quenched by adding 10 ml
of 3M HCl, and samples were placed on ice. Next, 20 ml of reaction mix 1 was
added to 200 ml of reaction mix 2 (1 unit bovine liver glutamate dehydrogenase
(Sigma-Aldrich), 80mM Tris-HCl pH 9.4, 200mM hydrazine, 0.25mM ADP,
2mM NAD). The samples were mixed and incubated for 1 h at room temperature.
The A340 was then determined against a blank in which a heat-inactivated
mitochondrial sample was added to reaction mix 1. A standard curve was also
prepared by adding known amounts of glutamate to reaction 2. This allowed the
amount of glutamate generated during reaction 1 to be determined. All assays
were carried out in triplicate, and the mean and s.d. calculated.
Real-time PCR analysis. Total RNA was extracted from cells using the RNeasy
mini kit (QIAGEN), and cDNAs were prepared using the SuperScript III ﬁrst-
strand synthesis system (Life Technologies). RT-PCR was carried out using the
7,500 fast real-time PCR system (Applied Biosystems), with cDNA as a template
and GLS primers GLS-F (50-TGTCACGATCTTGTTTCTCTGTG-30) and
GLS-R (50-TCATAGTCCAATGGTCCAAAG-30). Primers for mouse GAPDH
(mGAPDH-F, 50-ACAGTCCATGCCATCACTGCC-30 and mGAPDH-R, 50-GCC
TGCTTCACCACCTTCTTG-30) or human ACTB (hACTB-F, 50-CATCGAGCA
CGGCATCGTCA-30 and hACTB-R, 50-TAGCACAGCCTGGATAGCAAC-30)
were used as endogenous controls, as appropriate. All reactions were carried out
using POWER SYBR green PCR master mix (Life Technologies). At least three
replicates of each PCR were carried out.
Chromatin immunoprecipitation. Chromatin immunoprecipitations were
performed using the SimpleChIP enzymatic chromatin IP kit (Cell Signaling
Technology), following the manufacturer’s instructions. MDA-MB-231 cells
(5 15 cm dishes at B85% conﬂuency) were used as the source of chromatin.
Analysis following chromatin digestion showed that DNA was digested to
fragments of the desired size (150–900 bp, equivalent to 1–5 nucleosomes).
An antibody against endogenous c-Jun (Cell Signaling Technology, 9165) was
used to immunoprecipitate complexes containing c-Jun. Following reversal of
protein–DNA complexes and puriﬁcation of DNA, RT–PCR was carried out as
described above but using the puriﬁed DNA as a template. Three primer sets were
designed to amplify 100–200 bp fragments centred on the putative c-Jun binding
site of the GLS promoter at position  188 bp relative to the TSS. Set 1 (forward
and reverse): 50-CCCTAGTACCCAACTAGGCTAGCC-30 and 50-CCTCTCTTT
TGATTGGCGATTAGGG-30. Set 2 (forward and reverse): 50-GCGTGCAGAAAG
TGGCTACTGAGC-30 and 50-CTCTCGGCTCTGGGTGCGCGGAGAG-30.
Set 3 (forward and reverse): 50-CCTCGGAGTTGGCACGGCGTGCAG-30 and
50-GGCAGTCAAATTTCTCTCGGCTC-30 .
RNA interference. Knockdown of JUN expression in BT-549 cells was achieved
using Silencer select pre-designed and validated siRNA (Life Technologies).
Because endogenous c-Jun levels are so high in this cell line, two rounds of siRNA
treatment were required to achieve effective knockdowns. Two siRNA products
(manufacturer ID # s7658 and s7659) were used, along with the Silencer select
negative control no. 1 siRNA. Transfections were carried out in 10 cm dishes
at B80% conﬂuency using Lipofectamine 2000 transfection reagent (Life
Technologies) and following the manufacturer’s instructions. The ﬁnal siRNA
concentration was 15 nM in all cases. Transfection medium was replaced with fresh
growth medium 5 h after treatment. At 48 h following the initial transfection, the
procedure was repeated, and cells were collected after a further 48 h.
Stable cell lines. Transfection of breast cancer cell lines with plasmid DNA
constructs (pCDNA3.1 or pCDNA3.1-JUN) was carried out using Lipofectamine
2000 transfection reagent (Life Technologies), following the manufacturer’s
instructions. At 48 h after transfection, cells were placed under G418 selection
by supplementing the growth medium with G418 (500 mgml 1 for MCF7, and
800 mgml 1 for MDA-MB-468). Growth medium was replaced every 48 h for
2–3 weeks, until isolated colonies (B2mm diameter) were apparent on the plate.
At this point, individual clones were transferred to 12-well dishes and expanded in
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250mgml 1 G418 for further analysis. Appropriate clones were screened for
c-Jun-V5 by western blot, and V5-positive clones were maintained in 250 mgml 1
G418.
TCGA data. The Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma
(TCGA, provisional) data set was accessed, all data were analysed, and correlation
plots prepared using the cBioportal45,46 suite of tools (www.cbioportal.org).
Statistical analyses. All differences were analysed with Student’s t-test. A P value
o0.05 was considered to be signiﬁcant and marked (*), and a P value below 0.01
was considered to be highly signiﬁcant and marked (**).
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